Accession Number: | 0001209191-21-051885 |
Date: | 2021-08-13 |
Issuer: | PRELUDE THERAPEUTICS INC (PRLD) |
Original Submission Date: |
SCHERLE PEGGY
C/O PRELUDE THERAPEUTICS INCORPORATED
200 POWDER MILL ROAD
WILMINGTON, DE 19803
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2021-08-13 | M | 558 | a | $1.89 | 173,478 | direct | ||
COMMON STOCK | 2021-08-13 | M | 1,728 | a | $1.43 | 175,206 | direct | ||
COMMON STOCK | 2021-08-13 | S | 2,286 | d | $35.07 | 172,920 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
EMPLOYEE STOCK OPTION (RIGHT TO BUY) | 1.89 | 2021-08-13 | deemed execution date | M | 558 (d) | 2030-03-26 | common stock 558 | $1.89 | 42,672 | direct | ||
EMPLOYEE STOCK OPTION (RIGHT TO BUY) | 1.43 | 2021-08-13 | deemed execution date | M | 1,728 (d) | 2028-11-12 | common stock 1,728 | $1.43 | 34,732 | direct |
ID | footnote |
---|---|
f1 | certain of the shares are subject to forfeiture to the issuer if underlying vesting conditions are not met. |
f2 | the transactions reported on this form 4 were effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person. |
f3 | the price reported in column 4 is a weighted average price. these shares were sold in multiple transactions at prices ranging from $35.00 to $35.23, inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
f4 | the stock option vested as to 25% of the total shares monthly beginning on march 6, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the reporting person's provision of service to the issuer on the vesting date. |
f5 | the stock option vested as to 25% of the total shares monthly beginning on november 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the reporting person's provision of service to the issuer on the vesting date. |